Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.75 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28653349 | 0.93 | AGTR2 (0.82) | AGTR2PPARGABCB11EGFRERBB2 | |
| SCHEMBL30539216 | 0.93 | AGTR2 (0.82) | AGTR2PPARGABCB11EGFRERBB2 | |
| SCHEMBL30206762 | 0.93 | AGTR2 (0.82) | AGTR2PPARGABCB11EGFRERBB2 | |
| SCHEMBL21083669 | 0.93 | AGTR2 (0.67) | AGTR2PPARGABCB11EGFRERBB2 | |
| SCHEMBL30849967 | 0.93 | AGTR2 (0.67) | AGTR2PPARGABCB11EGFRERBB2 | |
| SCHEMBL21253137 | 0.92 | AGTR2 (0.65) | AGTR2PPARGABCB11EGFRERBB2 | |
| Azilsartan SCHEMBL29687472 | 0.92 | AGTR2 (0.72) | AGTR2PPARGABCB11EGFRERBB2 | |
| Azilsartan SCHEMBL167538 | 0.92 | AGTR2 (0.72) | AGTR2PPARGABCB11EGFRERBB2 | |
| SCHEMBL15645426 | 0.91 | AGTR2 (0.72) | AGTR2PPARGABCB11EGFRERBB2 | |
| Azilsartan SCHEMBL15552225 | 0.91 | AGTR2 (0.71) | AGTR2PPARGABCB11EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673274-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL | JUBILANT GENERICS LTD (IN) | 2019-07-17 | — | — | EP | claimed |
| US-9233955-B2 | Process for the preparation of azilsartan medoxomil | JUBILANT LIFE SCIENCES, LTD. (IN) | 2016-01-12 | — | — | US | claimed |
| EP-2673274-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL | Jubilant Life Sciences Limited (IN) | 2013-12-18 | — | — | EP | claimed |
| WO-2012107814-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL | JUBILANT LIFE SCIENCES LIMITED (IN) | 2012-08-16 | — | — | WO | claimed |
| CN-118955399-A | Preparation method of azilsartan impurity N | 北京爱科姆科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-115028589-A | Preparation method of azilsartan process impurity | 浙江普洛家园药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2020101450-A1 | DERIVATIVE COMPOUNDS OF AZILSARTAN, INTERMEDIATES THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 엠에프씨 주식회사 | 2020-05-22 | — | — | WO | disclosed |
| EP-2673274-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL | JUBILANT GENERICS LTD (IN) | 2019-07-17 | — | — | EP | disclosed |
| EP-2673274-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL | JUBILANT GENERICS LTD (IN) | 2019-07-17 | — | — | EP | disclosed |
| WO-2016147120-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE AZILSARTAN | SMILAX LABORATORIES LIMITED (IN) | 2016-09-22 | — | — | WO | disclosed |
| EP-2681201-B1 | A METHOD OF MANUFACTURING 2-ETHOXY-1-(2'-((HYDROXYAMINO)IMINOMETHYL)BIPHENYL-4-YL) METHYL)-1H-BENZO(D)IMIDAZOLE-7-CARBOXYLIC ACID AND ITS ESTERS | ZENTIVA KS (CZ) | 2016-08-24 | — | — | EP | disclosed |
| US-9233955-B2 | Process for the preparation of azilsartan medoxomil | JUBILANT LIFE SCIENCES, LTD. (IN) | 2016-01-12 | — | — | US | disclosed |
| EP-1857457-B1 | Benzimidazole derivative and its use as AII receptor antagonist | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7572920-B2 | Benzimidazole derivative and use as a II receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-11 | — | — | US | disclosed |
| EP-2058010-A1 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-1857457-A2 | Benzimidazole derivative and its use as AII receptor antagonist | Takeda Pharmaceutical Company Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1718641-B1 | BENZIMIDAZOLE DERIVATIVE AND ITS USE AS A II RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7157584-B2 | Benzimidazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060281795-A1 | Benzinidazole Derivative and Use As AII Receptor Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-12-14 | — | — | US | disclosed |
| US-20050187269-A1 | Benzimidazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281795-A1 | Benzinidazole Derivative and Use As AII Receptor Antagonist | AGTR1, AGTR2, GPR119 | AGTR2 2/4885PPARG 793/4885ABCB11 435/4885 |
| US-20050187269-A1 | Benzimidazole derivative and use thereof | REN, H1-3, GPR119 | AGTR2 40/4885PPARG 1288/4885ABCB11 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.